[Practical management of adalimumab].
Adalimumab, approved in the United States and Europe for the treatment of active rheumatoid and psoriatic arthritis and ankylosing spondylitis, might be used previously in the treatment of plaque psoriasis as "compassionate use drug." It should be remembered that its use should be in adults with moderate-severe psoriasis who, for some reason, do not tolerate or respond to the other existing systemic therapies or to phototherapy. Prior to its use, a detailed clinical history should be obtained with the study of the background of tuberculosis, and pregnancy and Mantoux tests should be performed. The current recommended dose for induction is 80 mg in week 0, followed by 40 mg the first week and maintenance dose of 40 mg every two weeks. Revisions should be performed every 4 weeks in the first three months of treatment and can be spaced after that, according to the evolution. It should be withdrawn if the patient is going to undergo surgery and vaccines with live agents are not recommended while the patient is on this treatment.
Avalos
P
P
Departamento de Dermatología. Hospital Universitario Virgen de la Macarena. Sevilla. España. camachodp@medynet.com
Camacho
F M
FM
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab